Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
ARYx Therapeutics, Inc. discovers and develops drugs for large, chronic disease markets. Its products include Naronapride, a proprietary serotonin type 4 (5HT4) for the treatment of multiple gastrointestinal disorders, Budiodarone, a proprietary compound in Phase 2 development for the treatment of atrial fibrillation, Tecarfarin, a novel compound for oral anti-coagulation therapy, and ATI-9242, a typical antipsychotic for the treatment of schizophrenia and other psychiatric disorders. The company was founded on February 28, 1997 by Peter G. Milner and Pascal Druzgala and is headquartered in Fremont, CA.
No news articles found for ARYx Therapeutics.
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
